Novartis intends to purchase bulk mRNA active ingredient from BioNTech and fill it into sterile vials for shipment back to BioNTech for distribution.
Novartis has agreed to expand its fill-and-finish support for the Pfizer/BioNTech COVID-19 vaccine by using manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022, according to the Swiss drugmaker.
Novartis intends to purchase bulk mRNA active ingredient from BioNTech and fill it into sterile vials for shipment back to BioNTech for distribution.
This new agreement builds on an earlier agreement for the fill and finish of more than 50 million doses at the Novartis Stein site in Switzerland in 2021.
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…
https://youtu.be/mdl3AFFFcuk?si=i2cYzTX7WJ-z6wRp Does Chyawanprash Help in Cough & Cold? Exploring Its Benefits and Efficacy Chyawanprash, a…
Walk In Winter: In winter, the time from 7:00 AM to 9:00 AM is considered…
Does Maida Stick To Your Gut Lining: In this article, we debunk the common myth…
https://youtu.be/4NTKSfNf1TM?si=Y4xkEOKDUvqpIEZt The Disadvantages of Heating Packaged Milk Milk is a staple in many households and…
A recent study has revealed a growing mental health crisis among teenagers globally, with nearly…